長實減價一成促銷九龍兩盤 涉20伙貨尾 VIVA悅目折扣增至15％
1 :
GS(14)@2016-05-19 02:06:18http://property.mpfinance.com/cf ... 0518/paa01/laa1.txt
【明報專訊】今年以來在本港主力銷售貨尾、過去5個月暫時累售約260伙的長實地產（1113），繼公布為旗下樓盤提供八成按揭後（包括一、二按，據悉不需作壓力測試），昨再出招催谷貨尾銷情。旗下馬頭圍道VIVA、紅磡悅目兩個樓盤，除將直減樓價折扣增至15％及15.5%外（比去年提高1.5%至3％不等），亦新增代繳7.5%印花稅及不選用二按可享2％回贈等優惠，變相整體減價逾10％。
明報記者 方可兒、林尚民
長實去年中開售的單幢盤VIVA，現餘5伙1房標準和特色戶、及11伙2房戶。價單顯示，1房戶直減折扣由12%增至15%，另新增為買家代繳7.5%印花稅（若買家繳付印花稅金額低於7.5%，差額將用作支付成交金額），及2％回贈予沒選用二按的買家。以31樓實用331方呎A室一房為例，扣除所有折扣及回贈，單位最終售價約522萬元，比去年88折後折實約597萬元，廉宜13％。
元朗世宙新增最多12萬回贈
至於僅餘4伙貨尾的悅目（1伙標準2房戶、3伙頂層特色戶），其中特色戶直減折扣由14％增至15.5%；同樣，長實為買家代繳7.5%印花稅、及2％現金回贈予沒有選用二按的買家，餘下單位變相減幅逾7%至9%。
此外，同系現餘234伙貨尾的元朗世宙，亦為購買指定2房、3房戶的買家，提供8萬及12萬元現金回贈，優惠周六生效，至本月底（31日）。
郭炳湘：對長實全權銷售君柏有信心
另長實地產執行董事趙國雄日前表示，與郭炳湘合作的亞皆老街君柏，集團與伙伴對市場看法不同；而君柏3月煞停銷售後仍未再推出市場。郭炳湘透過發言人回應說，對樓市中長期前景充滿信心，君柏銷售由長實全權負責、對長實絕對有信心亦沒任何意見。郭形容君柏位處傳統豪宅區，是難得項目。
南豐西半山羅便臣道80號，早前雖已提供八成一按按揭，昨新增首兩年「免息免供」計劃，第3、4年定息2.75厘，其後為P（P現為5厘），最長還款年期20年。
另信置（0083）西貢逸瓏園首錄撻訂，1座2樓實用994方呎E室本月初原以1341萬元售出，買家撻訂料遭殺訂5%涉67萬元。逸瓏園去年底開售，至上月突擊變相劈價逾一成，至今累售近90伙。
興勝稍後上載The Grampian樓書
興勝項目管理董事周嘉峰表示，由該公司負責銷售的九龍嘉林邊道新盤The Grampian，料月底獲批入伙紙，擬下月上載樓書、7月現樓發售；項目提供14伙，標準戶全為實用2077方呎4房戶。
長實Viva減價一成促銷
1 :
GS(14)@2016-05-21 13:09:11【本報訊】今年賣樓成績大落後的長實（1113），連續兩日出招谷旗下多個貨尾盤，先是推出最高八成按揭，至昨日三個貨尾盤各自增加優惠，變相減價，當中減價幅度最多的是紅磡馬頭圍道Viva，一房單位最多減價一成。據價單顯示，紅磡Viva買家在無採用二按的情況下購入400方呎以內一房單位，可獲發展商提供最高15%直減樓價折扣及成交價9.5%現金回贈，較過去僅最高12.5%直減樓價折扣附8.8萬元電器禮券，變相減價逾一成，兩房戶減幅則較少。系內同區利工街項目悅目亦引同類新優惠，特色戶實際減幅近一成。
逸瓏園錄首宗撻定
元朗世宙推出新優惠，買家5月31日前購買指定三房戶可獲額外12萬元現金回贈，而兩房戶則有8萬元回贈。集團執董趙國雄周一表示，與馬頭角君柏的合作夥伴郭炳湘對於後市看法存差異，郭炳湘昨透過發言人回應，對本港樓市中長線前景有信心，而君柏由長實方面全權負責，對合作夥伴有信心。另外，信置（083）西貢新盤逸瓏園首宗撻定，1座低層E室本月8日以1,341.8萬元售出，惟近日交易再無進展，料67萬元遭發展商沒收。嘉里（683）等沙田玖瓏山自首季交樓後不斷有買家撻大定，上月至今累積七宗，料殺定逾千萬，當中「街市大亨」周起鴻再撻1伙月瓏閣高層三房戶。會德豐（020）Savannah今晚將進行次輪銷售108伙，累收2,299登記，超額認購逾20倍。發展商指對銷情有信心，最快即晚加推並於周日賣樓。
來源:
http://hk.apple.nextmedia.com/financeestate/art/20160518/19616325
【真活佛Viva】日本美和尚開酒吧 摸酒杯底解眾生惑
1 :
GS(14)@2017-06-25 09:32:28藤岡善信開酒吧傳佛理，希望吸引年輕人。
弘揚佛法，一定是碎碎念佛機？一次資料搜集時，發現受訪者的一條短片，六位僧人不拿木魚拿結他，將佛經改做搖滾金曲，《般若心經》隨住電流節拍急促起動，台下觀眾忘我合十，場面仲勁過至尊寶十次「波若波羅密」。唔夠癲？下條片大師們仲crossover牧師band，將聖詩與佛經推至共融境界，宗教領袖都冇咁勁。你可以話佢離經叛道，佢就話來到21世紀，宣道都可以好貼地。
找上藤岡善信，是想採訪他的佛門酒吧。在東京四局谷三丁目的小巷弄，「坊主Bar」藏在不起眼的角落，簡潔的白燈招牌卻夠顯眼。鑽上舊樓房2樓，大概可容納十多人的小空間，他身穿一身僧衣，在吧枱後方忙着整理。
藤岡善信與另外五位僧人組成VowzBand，將佛經改做搖滾金曲。
主打雞尾酒叫做「極樂淨土」，用熱情果酒、紅莓、芒果汁等沖調。（$57）
胡麻油炒生麩，$50。
「日本佛教跟其他亞洲國家之別，普通的生活是被允許的，因此是在普通生活的基礎上再去信佛，所以說是一邊做凡人一邊信佛教。」自佛教紮根日本，對人民的影響力很大，戰國時代就形成不少武僧團勢力。到明治年代，政府為了削弱這種精神崇拜，就准許和尚飲酒食肉、娶妻生子，將其「凡人化」。除了部份門派，大多數都不必嚴守戒律。即便如此，以開酒吧來傳道，也屬相當破格。
藤岡善信入選美男和尚圖鑑。
店內用「緣」取代「元」。
開店前，他會在佛像前念經。
酒吧在東京四谷三丁目的小巷內。
「像一般寺廟的話，除了做法事、葬禮，其他時間跟一般人接觸很少，正常不會去寺廟的。我就想怎麼才能走出來，讓更多人可以接觸佛教。」他平日早上會先到寺廟做法事，傍晚七時來開店。客人來到通常與他傾心事，談感情、事業問題，他則會用佛學上的知識，去幫他們解惑。他坦言女性OL客最多，我還在究其因時，發現吧枱上一本「美男和尚40選」的書，如徵友雜誌般有兩版他的詳細介紹。除了在酒吧，他亦的樂隊亦常有演出，雖未至走紅，但辦小型演奏會仍備受捧場。看來日本在宗教年輕化一事上，走得很前。
VowzBar地址：東京新宿區荒木町6 AG大廈2F時間：7pm-1am（星期日休息）網址：
http://vowz-bar.com交通：地下鐵四谷三丁目站步行5分鐘記者：甄俊宇攝影：梁志永2017果籽繼續認真知味。識買惜用。行以求知。好事多為。重修舊好。緊貼果籽報道，即like：
http://fb.me/AS.AppleDaily
來源:
http://hk.apple.nextmedia.com/su ... t/20170624/20066673
維亞生物科技控股集團(Viva Biotech Holdings) 專區
1 :
GS(14)@2018-07-24 23:16:07http://www.vivabiotech.com/pauseing.jsp
網址
2 :
GS(14)@2018-07-24 23:17:41http://webcache.googleuserconten ... zh-TW&ct=clnk&gl=hk
3 :
GS(14)@2018-07-24 23:17:51https://www.businesswire.com/new ... ls-Join-Forces-Form
SHANGHAI & REHOVOT, Israel.--(BUSINESS WIRE)--Viva Biotech Ltd., a leading company in structure-based and fragment based drug discovery services, based in Shanghai, China, and HQL Pharmaceuticals Ltd., a drug discovery company utilizing its super-power proprietary ChemSpace Scanner (CSS™) computational technology, based in Rehovot, Israel, today announced that they have entered into a strategic alliance to jointly provide a fully-integrated drug discovery services, focused on leads generation based on fragment screening.
Under the terms of the agreement, Viva and HQL will jointly provide their customers accelerated and cost effective comprehensive drug discovery services, from targets into early development, with an aim of providing set of diverse high quality novel drug candidates with a wide IP protection for the client's targets,. The collaboration is based on Viva's world-class SBDD / FBDD capabilities and HQL's fragments to leads breakthrough computational solution.
Dr. Cheney Mao, CEO of Viva, said: "Viva Biotech works on several hundred potential drug targets and runs active FBDD/SBDD drug discovery projects for several dozen major pharmaceutical companies every year. We are very pleased to establish this strategic alliance with HQL and access to their powerful computational chemistry technology. By synergizing our capabilities with HQL's, we expect to offer our existing and new customers a clear and substantial added value to their projects."
Tal Parnes, CEO of HQL, said: "Once we had a lab proof of our fragments to leads breakthrough capabilities, we were looking to partner with a world-class SBDD/FBDD CRO, to embed these capabilities into a fully integrated drug-discovery service. We are very happy that Viva's team sees eye to eye with us the potential of this collaboration and we are thrilled for the opportunity to jointly offer this toolkit with Viva."
About Viva Biotech Ltd.
Viva Biotech (
www.vivabiotech.com) is privately owned and financed by leading investors in the United States. It is a well-established contract research organization that provides preclinical drug discovery research services to the pharmaceutical industry worldwide. The core capabilities of the company include its leading protein crystallography and structure based drug design, a MS based screening technology with a proprietary fragment library, a novel proprietary technology for GPCR target preparation, crystallization and applications for both small molecule and large molecule drug discovery, lead antibody generation capability by phage display or hybridoma approach, and other preclinical drug discovery research capabilities such as DMPK, animal disease models for CNS and oncology.
About HQL Pharmaceuticals Ltd.
Based in Rehovot, Israel, HQL Pharmaceuticals (
www.hql.co.il) is a Biotech company that utilizes its proprietary computational technology to fundamentally change the way drug discovery is conducted. HQL's revolutionary CSS™ computational technology enables highly efficient screening of chemical libraries of more than 20 orders of magnitude higher than currently possible, against high resolution, 3 dimensional drug models. The CSS platform is designed to tackle extremely tough challenges such as linking fragments into drug-like leads and the design of small molecule inhibitors of protein-protein interaction. HQL is privately owned and financed by investors in Israel and in the US.
Contacts
Viva Biotech (Shanghai) Limited
Zengquan Wang PhD.
CBO
021-60893288-ext.8408
011-86-13918635856
[email protected]
or
HQL Pharmaceuticals Ltd.
Tal Parnes
CEO
+972-54-4656035
[email protected]
4 :
GS(14)@2018-07-24 23:18:03http://www.hkexnews.hk/APP/SEHK/ ... ls-2018072002_c.htm
招股書